Targeting SORT1 Positive Cancers
Christian Marsolais, PhD, Chief Medical Officer of Theratechnologies, discusses three studies presented at the American Association for Cancer Research (AACR) conference involving sudocetaxel zendusortide.
Sudocetaxel zendusortide (TH1902) proprietary peptide linked to docetaxel – a cytotoxic agent used to treat many cancers. It is currently being investigated to treat tumors that express the sortilin (SORT1) receptor.
At the ACCR annual meeting , data from three preclinical studies were presented that highlighted the potential efficacy of sudocetaxel zendusortide.
In the first AACR poster, researchers reported that sudocetaxel zendusortide induces immune cell infiltration and potentiates the anti-tumoral activity of anti-PD-L1 therapy in a melanoma mouse model. Dr. Marsolais noted that “Given that preclinical results showed a statistically significant improvement in the efficacy of an anti-PD-L1 inhibitor for tumors treated with sudocetaxel zendusortide in contrast to docetaxel, we are hopeful that further research with combination therapy may also lead to improved clinical outcomes.”
The second AACR poster sudocetaxel zendusortide demonstrated significant anticancer properties against SORT1-positive triple-neagative and Herceptin-resistant HER2-positive breast cancer models. The researchers concluded the results warrant further evaluation for sudocetaxel zendusortide as a possible treatment of patients with SORT1-positive breast cancers.
The third poster used immunohistochemistry to screened 19 cancer types to assess which cancer types have high levels of SORT1 expression. Cancer types with high scores included endometrial cancer, thyroid cancer, melanoma, bladder cancer, testis cancer, and small cell lung cancer.
As noted by Dr. Marsolais, the results of the three presentations at AACR 2023 demonstrate the validity of pursuing a drug candidate that targets SORT1 positive tumors.
Watch video Targeting SORT1 Positive Cancers online without registration, duration hours minute second in high quality. This video was added by user CheckRare 08 May 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 23 once and liked it people.